Christine M. Chresta

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 790 citations · Full text

Mtorc2 Substrate Akt, Cell Death, Pharmacotherapy +21

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

Juan Manuel García‐Martínez, Jennifer L. Moran, Rosemary G. Clarke et al. · Biochemical Journal · 2009 · 460 citations · Full text

Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial‐to‐mesenchymal transition

Paul Roepman, Andreas Schlicker, Josep Tabernero et al. · International Journal of Cancer · 2013 · 346 citations · Full text

Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio.

Christine M. Chresta, John R. Masters, John A. Hickman · PubMed · 1996 · 262 citations

Apoptosis, Immunology, Cell Death +19

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Jonathan R. Dry, Sandra Pavey, Christine A. Pratilas et al. · Cancer Research · 2010 · 261 citations · Full text

Cell Subsets, Tumor Biology, Transcriptional Regulation +17